Role of Serum Hyaluronic Acid in Predicting Necroinflammatory Activity of the Nonalcoholic Fatty Liver Disease

Overview

Journal Hepatol Forum

Publisher Kare Publishing

Specialty Gastroenterology

Date 2022 Jul 5

PMID 35783474

Authors

Hakan Guveli

Oya Ovunc Kurdas

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Hyaluronic acid (HA), a fundamental component of the extracellular matrix, is associated with chronic liver diseases. The aim of this study was to investigate quantitative HA measurement as a noninvasive marker for steatosis and fibrosis staging in nonalcoholic fatty liver disease (NAFLD) with biopsy evidence.

Materials And Methods: In this study, 52 NAFLD patients with biopsy evidence and who met the inclusion criteria were included. Hepatic enzyme levels, HA levels, and other laboratory findings were examined. In addition, the degree of steatosis was determined via computed tomography (CT).

Results: According to the degree of steatosis, HA levels were 29.17±22.66, 39.85±60.28, and 32.05±19.40, respectively, and no significant difference was found between the groups (p=0.584). In addition, HA levels were not found to be significant according to the degrees of steatohepatitis (p=0.860). However, a statistically significant relationship was found between steatosis levels detected by CT and biopsy (p<0.01).

Conclusion: Serum HA level, other biochemical parameters, and steatosis severity measurement via CT did not appear to have any diagnostic value for nonalcoholic steatohepatitis. In this context, novel markers that may be useful for NAFLD diagnosis and severity assessment in risky individuals should be investigated.

References

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Neuschwander-Tetri B, Clark J, Bass N, Van Natta M, Unalp-Arida A, Tonascia J . Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010; 52(3):913-24. PMC: 3070295. DOI: 10.1002/hep.23784. View

Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G . Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017; 66(5):1486-1501. DOI: 10.1002/hep.29302. View

Parise E, Oliveira A, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H . Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int. 2006; 26(9):1095-9. DOI: 10.1111/j.1478-3231.2006.01356.x. View

Wang N, Dong H, Wei S, Lu F . Application of proton magnetic resonance spectroscopy and computerized tomography in the diagnosis and treatment of nonalcoholic fatty liver disease. J Huazhong Univ Sci Technolog Med Sci. 2008; 28(3):295-8. DOI: 10.1007/s11596-008-0315-2. View

Cen C, Wang W, Yu S, Tang X, Liu J, Liu Y . Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease. Hepatol Int. 2020; 14(5):808-816. DOI: 10.1007/s12072-020-10065-7. View

Baranova A, Younossi Z . The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology. 2008; 47(2):373-5. DOI: 10.1002/hep.22140. View

Ponomarenko Y, Leo M, Kroll W, Lieber C . Effects of alcohol consumption on eight circulating markers of liver fibrosis. Alcohol Alcohol. 2002; 37(3):252-5. DOI: 10.1093/alcalc/37.3.252. View

Argo C, Northup P, Al-Osaimi A, Caldwell S . Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009; 51(2):371-9. DOI: 10.1016/j.jhep.2009.03.019. View

10.

Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N . Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol. 2005; 11(4):476-81. PMC: 4250794. DOI: 10.3748/wjg.v11.i4.476. View

11.

McHutchison J, Blatt L, de Medina M, Craig J, Conrad A, Schiff E . Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol. 2000; 15(8):945-51. DOI: 10.1046/j.1440-1746.2000.02233.x. View

12.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A . The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33. PMC: 1636651. DOI: 10.1186/1471-230X-6-33. View

13.

Zheng M, Chengliang C, Chen Y, Gopal N, Ramesh R, Jiao J . Diagnostic performance of fibroscan and computed tomography in 322 normal alanine aminotransferase non-obese non-alcoholic fatty liver disease patients diagnosed by ultrasound. Int J Clin Pract. 2020; 74(12):e13635. DOI: 10.1111/ijcp.13635. View

14.

Zeng M, Lu L, Mao Y, Qiu D, Li J, Wan M . Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology. 2005; 42(6):1437-45. DOI: 10.1002/hep.20960. View

15.

Poynard T, Munteanu M, Charlotte F, Perazzo H, Ngo Y, Deckmyn O . Impact of steatosis and inflammation definitions on the performance of NASH tests. Eur J Gastroenterol Hepatol. 2017; 30(4):384-391. PMC: 5865485. DOI: 10.1097/MEG.0000000000001033. View

16.

Ueno T, Inuzuka S, Torimura T, Tamaki S, Koh H, Kin M . Serum hyaluronate reflects hepatic sinusoidal capillarization. Gastroenterology. 1993; 105(2):475-81. DOI: 10.1016/0016-5085(93)90722-o. View

17.

Baek J, Jung S, Shim J, Jeon Y, Seo E, Kim H . Comparison of Computed Tomography-based Abdominal Adiposity Indexes as Predictors of Non-alcoholic Fatty Liver Disease Among Middle-aged Korean Men and Women. J Prev Med Public Health. 2020; 53(4):256-265. PMC: 7411244. DOI: 10.3961/jpmph.20.140. View

18.

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

19.

Serfaty L, Lemoine M . Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2009; 34(6 Pt 2):634-7. DOI: 10.1016/S1262-3636(08)74597-X. View

20.

Orasan O, Ciulei G, Cozma A, Sava M, Dumitrascu D . Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med. 2016; 89(1):24-31. PMC: 4777465. DOI: 10.15386/cjmed-554. View